The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model.
Eur J Immunol. 2008 Jan;38(1):283-91. doi: 10.1002/eji.200737199.
Eur J Immunol. 2008.
PMID: 18085662